Ernexa Therapeutics Inc.
13F holders, Q3 2024 (September 30)20holders
2new positions
2sold out
$1.05avg. 13F price*
At the end of Q3 2024, 20 institutions reported holding Ernexa Therapeutics Inc. in their 13F filings, unchanged from Q2 2024. 2 opened new positions and 2 sold out. The largest holders were Corient Private Wealth LP ($276K), Cypress Point Wealth Management, LLC ($99K) and UBS Group AG ($88K).
- Company
- Ernexa Therapeutics Inc.
- Filed as
- ETERNA THERAPEUTICS INC (Q3 2024)
- CUSIP
- 114082209
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $122K |
| Exits | 2 | $8 |
All 13F filers, Q2 2024 → Q3 2024: 329,038 shares bought and 7,786 shares sold, net +321,252 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 20 holders
| Corient Private Wealth LP | 0.00% | Add +421.6% | 262,862 | $276K |
| Cypress Point Wealth Management, LLC | 0.04% | No change | 94,375 | $99K |
| UBS Group AG | 0.00% | New | 83,620 | $88K |
| Naviter Wealth, LLC | 0.01% | No change | 78,796 | $83K |
| Sippican Capital Advisors | 0.05% | Reduce -5.9% | 68,504 | $72K |
| Two Sigma Securities, LLC | 0.00% | New | 32,860 | $35K |
| Vanguard Group Inc. | 0.00% | No change | 26,099 | $27K |
| Geode Capital Management, LLC | 0.00% | Reduce -13.8% | 20,435 | $21K |
| BlackRock, Inc. | 0.00% | — | 14,919 | $16K |
| Avidian Wealth Enterprises, LLC | 0.00% | No change | 14,798 | $16K |
| Baldwin Wealth Partners LLC | 0.00% | No change | 8,544 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -3.5% | 4,994 | $5K |
| Montag A & Associates Inc. | 0.00% | No change | 212 | $223 |
| Bank of America Corp. | 0.00% | Add +324.1% | 123 | $129 |
| Morgan Stanley | 0.00% | No change | 50 | $53 |
| Activest Wealth Management | 0.00% | No change | 50 | $53 |
| Group One Trading LLC | 0.00% | No change | 19 | $20 |
| Citigroup Inc. | 0.00% | No change | 15 | $16 |
| JPMorgan Chase & Co. | 0.00% | No change | 14 | $15 |
| Aspire Private Capital, LLC | 0.00% | No change | 10 | $11 |
"% of holder's portfolio" is ERNEXA THERAPEUTICS INC's weight in each manager's 13F, not the share of Ernexa Therapeutics Inc. the manager owns.